DoubleBlind

DoubleBlind is a biannual print magazine, media, and courses company that covers stories about the expansion of psychedelics around the globe. They focus on listening to all perspectives, from indigenous communities who have preserved these medicines for millennia to those in society who need healing but don’t have access to it.

They cover various topics such as the depression epidemic, the corporatization of medicine, and the search for spirituality or other collective sense of meaning. They also cover how psychedelics have the potential to shift how the Western medical community perceives wellness more broadly. They believe that psychedelics are not just about the 1960s cultural revolution but a jumping-off point for exploring what it means to be well as individuals and a collective.

The company’s name, DoubleBlind, refers to the double-blind, randomized clinical trial and the fact that psychedelics have been banned from science for decades due to their association with a culture of radical expression that threatened the status quo. They hope to reflect on ethical questions that arise with the legalization of psychedelics such as cost, insurance coverage, and equity for patients and aspiring entrepreneurs.

Currently, DoubleBlind offers four introductory courses on psychedelics, ranging from microdosing to psychedelics and maternity.